Best Practices in the Treatment and Management of Systemic
Lupus Erythematosus (SLE): Addressing Disease Activity
and Flares for Improved Clinical and Economic Outcomes

Best Practices in the Treatment and Management of Systemic Lupus Erythematosus (SLE):
Addressing Disease Activity and Flares for Improved Clinical and Economic Outcomes
is a 3-part webcast series that will provide attendees with the latest information
in the treatment and management of
Systemic Lupus Erythematosus.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These are archives of live webinars held between July 12, 2018 and July 29, 2018.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.  

Each session has its own specific valid dates

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the posttest to receive continuing education credits. If you do not pass the posttest after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your posttest, you will automatically be given your certificate. To print or save your certificate, you will need to click on the “download” button and either print or save. 

This series is supported by an educational grant from GlaxoSmithKline 
 


 

Description:  Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary between people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. Diagnosis can be difficult and is based on a combination of symptoms and laboratory tests. Systemic lupus erythematosus (SLE) is the most common form of lupus and affects approximately 70 percent of an estimated 5 million people with lupus worldwide. Approximately 170,000-200,000 Americans live with SLE. Fortunately, over the past decade several new agents have become available, or are on the horizon. These options have proven to reduce lupus disease activity, and developments have been made to make administration easier for improving patient adherence and quality of life. With these recent developments, it is imperative to provide medical directors, primary care physicians, rheumatologists, and others on the interprofessional management team with updated guidelines and strategies for optimizing patient adherence and quality of life, with the ultimate goal of improving patient outcomes.

Addressing Disease Activity and Flares for an Individualized Approach to Managing Systemic Lupus Erythematosus (SLE) 

  • Discuss the impact of uncontrolled systemic lupus erythematosus (SLE) activity on organ damage, mortality, and costs to the healthcare system

  • Assess disease activity and severity, considering the diverse immunopathology and variable expression of SLE in different patients

  • Identifying patients who may be nonadherent to current SLE therapies that focus on reducing flares and disease activity

  • Review the safety and efficacy data on current and emerging SLE treatment to control disease activity and prevent or minimize disease flares, drug toxicity, and organ damage in patients with SLE

    Physician, Nursing and CMCN credits valid to September 30, 2019

A Managed Care Evaluation of Current Therapies and Updates in the Management of Systemic Lupus Erythematosus (SLE)

  • Review the safety and efficacy data on current and emerging SLE treatment to control disease activity and prevent or minimize disease flares, drug toxicity, and organ damage in patients with SLE

  • Address payer-and provider-related barriers to appropriate evidence-based use of BLyS-specific inhibitors

  • Apply methods to enable optimal cost management of SLE therapies to be realized by multiple stakeholders including managed care organizations

    Physician, Nursing and CMCN credits valid to September 30, 2019

Improving Patient Adherence and Quality of Life in SLE: Strategies for Improving Administration and Managing Adverse Events

  • Discuss methods to communicate effectively with SLE patients and the multidisciplinary team to understand and address the needs of each patient and improve treatment adherence, quality of life, and survival outcomes

  • Review new treatment options and strategies that may help improve patient adherence and quality of life, including self-administration of treatment

  • Integrate new evidence into practice to appropriately achieve treatment goals in individual patients with SLE

  • Examine adverse events associated with treatments that manage disease flares and discuss strategies to overcome these events

    Physician, Nursing and CMCN credits valid to September 30, 2019